Live Analyst Rating Changes 19320 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/David Saxon
NDM

David Saxon

Needham
Wall Street Analyst
★★★★☆
#458
on 13Foresight · ranked by our own returns
63%
Success Rate
+7.3%
Average Return
19 of 30 calls profitable · +3.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 63% of David Saxon's ratings turned a profit when each position was held for 2 year — averaging +7.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

64 Buy 43 Hold 0 Sell
David's Stock Coverage 17 ratings · 2026-08-07
Company Date Position Consensus ⓘ Price Target ⓘ 2-Yr Return vs S&P 500 ⓘ
SGHT
Sight Sciences
 Aug 06, 2026 HOLD Strong Buy
+18.3% avg upside
13 analysts
 — · ·
CARL
Carlsmed, Inc.
 Aug 06, 2026 BUY Strong Buy
+35.3% avg upside
6 analysts
$17.00
24.10% Upside
 · ·
RXST
RxSight
 Aug 06, 2026 BUY Hold
+49.7% avg upside
13 analysts
$11.00
80.95% Upside
 +0.0% ·
NVST
Envista Holdings
 Aug 06, 2026 HOLD Buy
+11.9% avg upside
19 analysts
 — · ·
ATEC
Alphatec Holdings
 Aug 05, 2026 BUY Strong Buy
+80.0% avg upside
23 analysts
$14.00
52.10% Upside
 -5.4% ·
AZTA
Azenta
 Aug 05, 2026 BUY Buy
+57.6% avg upside
13 analysts
$37.00
20.38% Upside
 · ·
SIBN
SI-Bone
 Aug 04, 2026 BUY Strong Buy
+43.4% avg upside
18 analysts
$27.00
48.90% Upside
 +0.0% ·
ALGN
Align Tech
 Jul 30, 2026 HOLD Strong Buy
+74.0% avg upside
21 analysts
 — -0.1% ·
GKOS
Glaukos
 Jul 30, 2026 BUY Strong Buy
-2.8% avg upside
21 analysts
$201.00
17.64% Upside
 +1.5% ·
BLCO
Bausch + Lomb Corporation
 Jul 29, 2026 HOLD Buy
+21.2% avg upside
19 analysts
 — +2.8% ·
STAA
Staar Surgical
 Jul 17, 2026 HOLD Hold
+46.8% avg upside
16 analysts
 — -8.8% ·
IRTC
Irhythm Technologies
 Jul 16, 2026 BUY Strong Buy
+32.2% avg upside
20 analysts
$255.00
99.11% Upside
 +11.1% ·
COO
Cooper Co
 Jun 05, 2026 BUY Buy
+80.7% avg upside
21 analysts
$86.00
17.31% Upside
 +10.0% ·
GMED
Globus Medical
 May 08, 2026 BUY Strong Buy
+14.6% avg upside
24 analysts
$117.00
44.38% Upside
 +4.0% ·
XRAY
DENTSPLY SIRONA
 May 06, 2026 HOLD Buy
+117.2% avg upside
25 analysts
 — +20.0% ·
CH:ALC
Alcon
 May 06, 2026 BUY Buy
+25.4% avg upside
35 analysts
$76.59
35.84% Upside
 +11.5% ·
CYRX
CryoPort
 May 05, 2026 BUY Strong Buy
+1.2% avg upside
15 analysts
$15.00
1.98% Upside
 +23.8% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
David Saxon — Frequently Asked Questions
How accurate are David Saxon's stock ratings?
Based on the calls 13Foresight could measure, about 63% of David's ratings were profitable over a one-year hold, with an average return of +7.3% per rating, or +3.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is David ranked on 13Foresight?
David Saxon is currently ranked #458 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does David cover?
David most recently has ratings on SGHT, CARL, RXST, NVST, ATEC, AZTA, SIBN, ALGN, GKOS, BLCO, STAA, IRTC and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.